FORE Biotherapeutics Announces Positive Outcome From a Planned Interim Efficacy Analysis for the FORTE Basket Study Evaluating Plixorafenib as a Monotherapy for Recurrent or Progressive BRAF V600 Primary CNS Tumors

businesswire

FORE Biotherapeutics Announces Positive Outcome From a Planned Interim Efficacy Analysis for the FORTE Basket Study Evaluating Plixorafenib as a Monotherapy for Recurrent or Progressive BRAF V600 Primary CNS Tumors – NEWSnet – News… as it used to be

More Press Releases

August 7, 2026

Dogfather Grooming Named “Best Pet Salon or Boutique” in CT Post’s Best of Connecticut Awards

August 7, 2026

Foot Drop Treatment Devices Market Report Examines Leading Companies And Growth Opportunities

August 7, 2026

When parents are stressed, kids get more screen time, study finds

August 7, 2026

FORE Biotherapeutics Announces Positive Outcome From a Planned Interim Efficacy Analysis for the FORTE Basket Study Evaluating Plixorafenib as a Monotherapy for Recurrent or Progressive BRAF V600 Primary CNS Tumors

Dogfather Grooming Named “Best Pet Salon or Boutique” in CT Post’s Best of Connecticut Awards

Foot Drop Treatment Devices Market Report Examines Leading Companies And Growth Opportunities

When parents are stressed, kids get more screen time, study finds

Blue Gems ABA and The Treetop ABA Sponsor Utah’s Largest Special Needs Family Expo – CHILL ACT